secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001193125-24-148112
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology discontinues IK-930, cuts workforce 53%, explores strategic options
--------------------------------------------------------------------------------

- Discontinued IK-930 (TEAD1 inhibitor) clinical development; winddown activities began.
- Reducing workforce by ~53% (18 employees); expected ~16 FTE remaining; cash costs ~$1.2M in Q2 2024.
- Continuing IK-595 (MEK-RAF glue) Phase 1; >80% pERK inhibition at 4h, >60% at 24h; dose escalation ongoing.
- Cash, equivalents and marketable securities $157.3M as of March 31, 2024.
- Board authorized exploration of strategic alternatives including acquisition, merger, sale, or partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/0001193125-24-148112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/d817758d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-148112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer